Contact Us
Find A Doctor

Copaxone Dry AMD Therapy

Study Title

Weekly Vaccination with Copaxone as a Potential Therapy for Dry Age Related Macular Degeneration

Enrollment Status:

Closed to Enrollment


The purpose of this study is to evaluate how tolerable, safe, and effective it is to give Copaxone subcutaneous injections to adults with dry age related macular degeneration (Dry AMD).


Ages Eligible for Study: 50 years old and older

Genders Eligible for Study: Both

Inclusion Criteria

  • Subjects with the diagnosis of dry age related macular degeneration

  • Aged 50 to 75 years.

  • Must have the presence of drusen and no geographic atrophy


Contact Us

Dr. Richard Rosen, Principal InvestigatorTel: (212) 979-4284

Katy Tai, Research ManagerTel: (212) 979-4251

Address310 E. 14th StreetNew York, NY 10003

View all locations